Last updated: Jul 11, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT07357597 | 4 | An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. | Trop2 -- antibody-drug conjugate (datopotamab deruxtecan) with corticosteroid prophylaxis |
| NCT06695845 | 2 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | HER2 -- bispecific antibody |
| NCT06312176 | 3 | A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | Trop2 -- antibody-drug conjugate (sacituzumab tirumotecan); PD-1 -- immune checkpoint inhibitor (pembrolizumab); chemotherapy (paclitaxel, nab-paclitaxel, capecitabine) |
| NCT06966700 | 3 | A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | Trop2 -- antibody-drug conjugate (ADC); PD-1 -- immune checkpoint inhibitor (monoclonal antibody) |
| NCT06841354 | 3 | A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) | Trop-2 -- antibody-drug conjugate (sacituzumab govitecan) + PD-1 -- immune checkpoint inhibitor (pembrolizumab) |
| Sponsor | Recruiting trials |
|---|---|
| Fudan University | 111 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 40 |
| Memorial Sloan Kettering Cancer Center | 35 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 30 |
| M.D. Anderson Cancer Center | 29 |
Countries/regions with the most active trial sites for breast cancer. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Oct 1, 2026 | NCT07553390 | Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers | TGFBR2 -- knockout; TROP2 -- chimeric antigen receptor (CAR) NK cells; HER2 -- antibody-drug conjugate (trastuzumab deruxtecan) |
| Oct 2026 | NCT07581314 | Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) | Telomerase -- inhibitor (Zn-Telomir) |
| Sep 15, 2026 | NCT06148038 | CBD for Breast Cancer Primary Tumors | Cannabinoid receptor -- cannabinoid receptor agonist (CBD) |
| Sep 2026 | NCT07545122 | A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers | Nectin-4 -- bispecific antibody (CT-202) |
| Aug 1, 2026 | NCT07300475 | Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients | PD-1 + chemotherapy agents -- immune checkpoint inhibitor + chemotherapy |
| Jul 3, 2026 | NCT07601620 | A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer | HER2 -- monoclonal antibody (HLX319, biosimilar to Phesgo) |
| Jul 1, 2026 | NCT07494448 | Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer | HER2 -- bispecific antibody plus HER2 tyrosine kinase inhibitor |
| Jul 2026 | NCT07136428 | Asciminib in HER2+ Breast Cancer Brain Metastases | BCR-ABL allosteric site -- allosteric inhibitor + HER2 -- monoclonal antibody |
You've seen the breast cancer landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.